CA3082625C - Procedes d'utilisation et compositions contenant du dulaglutide - Google Patents

Procedes d'utilisation et compositions contenant du dulaglutide

Info

Publication number
CA3082625C
CA3082625C CA3082625A CA3082625A CA3082625C CA 3082625 C CA3082625 C CA 3082625C CA 3082625 A CA3082625 A CA 3082625A CA 3082625 A CA3082625 A CA 3082625A CA 3082625 C CA3082625 C CA 3082625C
Authority
CA
Canada
Prior art keywords
dulaglutide
dose
subject
once weekly
weeks
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3082625A
Other languages
English (en)
Other versions
CA3082625A1 (fr
Inventor
David Andrew Cox
Zvonko Milicevic
Lai San Tham
Andrew Gordon Werner
David Bradley Woodward
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Priority claimed from PCT/US2018/060716 external-priority patent/WO2019103875A2/fr
Publication of CA3082625A1 publication Critical patent/CA3082625A1/fr
Application granted granted Critical
Publication of CA3082625C publication Critical patent/CA3082625C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

La présente invention concerne des procédés d'utilisation de nouvelles doses de dulaglutide et des compositions contenant de telles doses plus élevées de dulaglutide.
CA3082625A 2017-11-21 2018-11-13 Procedes d'utilisation et compositions contenant du dulaglutide Active CA3082625C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762589244P 2017-11-21 2017-11-21
US62/589,244 2017-11-21
PCT/US2018/060716 WO2019103875A2 (fr) 2017-11-21 2018-11-13 Procédés d'utilisation et compositions contenant du dulaglutide

Publications (2)

Publication Number Publication Date
CA3082625A1 CA3082625A1 (fr) 2019-05-31
CA3082625C true CA3082625C (fr) 2025-07-22

Family

ID=

Similar Documents

Publication Publication Date Title
AU2022203372B2 (en) Methods of using and compositions containing dulaglutide
JP6121403B2 (ja) ２型糖尿病患者の体重減少を誘導する際、または／および２型糖尿病患者の体重増加を防止するために使用するための組合せ医薬
TW202323296A (zh) 組合療法
JP2024129139A (ja) ベンラリツマブを使用して喘息の増悪率を低減する方法
JP2026048629A (ja) エキセンディン（９－３９）の緩衝製剤
EP2524693B1 (fr) Produit pharmaceutique destiné au traitement prophylactique ou thérapeutique de troubles accompagnés d'une angiogenèse oculaire et/ou d'une perméabilité vasculaire oculaire supérieure à la normale
JP2020100653A (ja) ベンラリツマブによる喘息症状の改善方法
TWI804692B (zh) 杜拉魯肽(dulaglutide)之治療用途
CA3082625C (fr) Procedes d'utilisation et compositions contenant du dulaglutide
EP4335438A1 (fr) Polythérapie avec de la vildagliptine et de la metformine
EP4360644A1 (fr) Efpéglénatide pour réduire le risque de développer une maladie cardiovasculaire ou un dysfonctionnement rénal
EA041605B1 (ru) Способы применения и композиции, содержащие дулаглутид
DK182293B1 (en) Semaglutide for use in medical therapy including weight management
HK40128497A (zh) 使用gip/glp1共激动剂用於治疗的方法
HK40127982A (zh) 使用gip/glp1共激动剂用於治疗的方法
HK40128498A (zh) 使用gip/glp1共激动剂用於治疗的方法
Dey et al. Renal safety profile of di-peptidyl-peptidase inhibitors: a review of available literature